Alpha Cubed Investments LLC reduced its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 70.2% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 68,262 shares of the company's stock after selling 161,076 shares during the quarter. Alpha Cubed Investments LLC's holdings in Merck & Co., Inc. were worth $6,127,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. Barnes Dennig Private Wealth Management LLC bought a new stake in shares of Merck & Co., Inc. during the 1st quarter valued at about $27,000. WealthTrak Capital Management LLC bought a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at about $35,000. MorganRosel Wealth Management LLC purchased a new position in shares of Merck & Co., Inc. during the 1st quarter valued at about $36,000. Spurstone Advisory Services LLC purchased a new position in shares of Merck & Co., Inc. during the 4th quarter valued at about $37,000. Finally, Hurley Capital LLC purchased a new position in shares of Merck & Co., Inc. during the 4th quarter valued at about $40,000. 76.07% of the stock is currently owned by institutional investors.
Insider Buying and Selling at Merck & Co., Inc.
In other news, SVP Dalton E. Smart III sold 4,262 shares of the business's stock in a transaction that occurred on Friday, April 25th. The stock was sold at an average price of $82.76, for a total transaction of $352,723.12. Following the transaction, the senior vice president owned 7,778 shares of the company's stock, valued at approximately $643,707.28. The trade was a 35.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.13% of the company's stock.
Merck & Co., Inc. Price Performance
Shares of MRK stock traded up $2.37 on Wednesday, reaching $83.74. The company's stock had a trading volume of 18,390,570 shares, compared to its average volume of 13,368,354. The stock's fifty day simple moving average is $79.06 and its 200-day simple moving average is $86.71. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $129.93. The company has a current ratio of 1.41, a quick ratio of 1.16 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $210.27 billion, a price-to-earnings ratio of 12.19, a price-to-earnings-growth ratio of 0.84 and a beta of 0.39.
Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its earnings results on Thursday, April 24th. The company reported $2.22 earnings per share for the quarter, beating analysts' consensus estimates of $2.16 by $0.06. Merck & Co., Inc. had a net margin of 27.27% and a return on equity of 43.23%. The firm had revenue of $15.53 billion during the quarter, compared to analyst estimates of $15.59 billion. During the same period last year, the firm posted $2.07 earnings per share. Merck & Co., Inc.'s revenue for the quarter was down 1.6% compared to the same quarter last year. Analysts forecast that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.
Merck & Co., Inc. Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Tuesday, July 8th. Stockholders of record on Monday, June 16th were given a dividend of $0.81 per share. This represents a $3.24 annualized dividend and a dividend yield of 3.87%. The ex-dividend date was Monday, June 16th. Merck & Co., Inc.'s dividend payout ratio is currently 47.16%.
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on MRK. Cantor Fitzgerald cut Merck & Co., Inc. from an "overweight" rating to a "cautious" rating in a research report on Tuesday, May 20th. Citigroup reaffirmed a "neutral" rating and set a $84.00 price objective (down from $115.00) on shares of Merck & Co., Inc. in a research report on Wednesday, May 14th. Wall Street Zen cut Merck & Co., Inc. from a "strong-buy" rating to a "buy" rating in a research report on Friday, April 25th. Finally, Guggenheim reaffirmed a "buy" rating and set a $115.00 price objective on shares of Merck & Co., Inc. in a research report on Thursday, April 17th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $109.19.
Get Our Latest Report on MRK
Merck & Co., Inc. Profile
(
Free Report)
Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Recommended Stories

Before you consider Merck & Co., Inc., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.
While Merck & Co., Inc. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.